Summary. Transgenic mice over-expressing human acetylcholinesterase (hAChETg) display memory impairments, cholinergic deficits and reduced dendritic branching. In this study, we found a reduced number of N-Methyl-D-Aspartate (NMDA) binding sites and reduced levels of low molecular weight (LMW) microtubule associated protein 2 (MAP-2), in addition to an increased number of a4 and a7 nicotinic receptor (nAChR) binding sites in the brain of hAChETg mice. Treatment with memantine, 20 mg=kg=day during 14 days, significantly increased the number of [ 125 I]abungarotoxin (a7 nAChR) binding sites in the frontal-and retrosplenial cortex of hAChE-Tg mice and synaptophysinand LMW MAP-2 levels in the cortex of both hAChE-Tg and FVB=N controls. The findings reveal an alteration of the glutamatergic system in hAChE-Tg mice. Whether the effect of memantine on a7 nAChRs, synaptophysin-and LMW MAP-2 levels is a direct effect, or an indirect effect via the NMDA receptors, has to be further evaluated.
Introduction
Neurodegenerative diseases are characterised by slow and progressive loss of neurons in different areas of the central nervous system, affecting multiple neurotransmitter systems in the brain. Although different cell groups are affected in each disease, they probably share common pathways involving complex molecular processes leading to degeneration.
Deficits in the cholinergic neurotransmitter system are observed in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (Nordberg, 1999; Perry, 2000) The neuronal nicotinic acetylcholine receptors (nAChRs) play a role in a variety of modulatory and regulatory processes in the brain, including memory and neuroprotection (Gray, 1996; Jonnala, 2001; Paterson, 2000) . Both the a4 and the a7 nAChRs are present in many brain regions receiving cholinergic innervation, although some suggestions regarding the a7 nAChRs propose an additional non-cholinergic distribution on glutamatergic axon terminals, mediating enhancement of glutamate release (Marchi, 2002; McGehee, 1995) . Glutamate has also been proposed to be involved in the pathophysiological mechanism of neurodegenerative diseases, where increasing concentrations of glutamate cause N-Methyl-D-Aspartate (NMDA) channels to remain open for a longer period of time, resulting in an increase of intracellular Ca 2þ , causing neurotoxicity (Meldrum, 1990) . In AD, glutamatergic neurons degenerate and studies have shown reductions in the concentration of glutamate . Reductions in NMDA receptor binding in the hippocampus and neocortex have also been reported (Greenamyre, 1993; Procter, 1990) .
Memantine is an uncompetitive NMDA antagonist with moderate affinity used as symptomatic treatment in AD. The neurobiological basis for the therapeutic activity of memantine is not fully understood. Pre-clinical studies of memantine revealed evidence of neuroprotection against NMDA induced neurotoxicity in the nucleus basalis magnocellularis (NBM) of rats (Wenk, 1997) and reversed the lesion-induced increase in reference memory errors in rats with entorhinal cortex lesions, indicating that under conditions of pathological impairment of brain structures such as entorhinal cortex lesion, memantine might produce beneficial effects on cognitive functions. (Zajaczkowski, 1996) . In clinical studies memantine reduced clinical deterioration in moderate-tosevere Alzheimer's disease (Reisberg, 2003) . Blockade of NMDA receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia. In addition, there is evidence that memantine acts as an open channel blocker at several ligand gated ion channels, for instance the human a4b2, rat a10=a9 as well as the human a7 nAChR (Buisson, 1998; Oliver, 2001; Maskell, 2003) .
Acetylcholinesterase (AChE) hydrolyses and inactivates acetylcholine, thereby regulating the concentration of the transmitter at the synapse. Besides this classical action AChE seems to have multiple activities, including neuritogenesis, cell adhesion, synaptogenesis and amyloid fibre assembly . A transgenic mouse model over-expressing human AChE (hAChETg), with a two-fold increase in enzyme levels in comparison to control mice, show behavioural disturbances, early onset loss of learning and memory capacities, progressive dendritic depletion, neuropathology related to stress and modified anxiety responses (Beeri, 1995 (Beeri, , 1997 Erb, 2001; Sternfeld, 2000) . Studies of the cholinergic activity in these mice have revealed increased a4 and a7 nAChRs as well as muscarinic M2 binding sites in brain, suggesting that these receptor subtypes play an important role in compensatory mechanisms facilitating the impaired cholinergic neurotransmission (Svedberg, 2002 (Svedberg, , 2003 . Furthermore, it could be of interest to investigate the effect of cholinergic deficits on other neurotransmitter systems. Studies of the glutamatergic neurotransmitter system have not been performed in these mice and little is known about how the excess of AChE activity influences other neurotransmitter system than the cholinergic. We focused on the NMDA receptor, since this receptor is ideally suitable for mediating plastic changes in the brain. The results may therefore provide important information about interactions between the cholinergic and the glutamatergic systems. We also wanted to investigate if the neuropathology in these mice in relation to the excess of AChE could be improved by memantine, which is known to act neuroprotective in animal models. 
Material and methods

Materials
Mice
The Principles of laboratory animal care (NIH publication No. 86-23, revised 1985) were followed. All animal experimental protocols were approved by the local Ethics Committee and carried out in accordance with the guidelines of The Swedish National Board for Laboratory Animals (CFN), (Dnr S80=01).
FVB=N mice carrying the human AChE cDNA under the control of 586 bp of the authentic human AChE promoter were originated by Beeri (1995) . Wild-type FVB=N mice (Bomice & Mollegard Breeding Laboratories) were used as controls. All mice were born and bred in our own colony and housed under the same conditions. The mice had access to food and water ad libitum and were maintained on a 12 h light=dark cycle. Ten five-months old hAChE-Tg mice and FVB=N mice were randomised into treatment s.c. with memantine 10 mg=kg twice a day for 14 days. Corresponding age-and sex-matched randomised control groups received 0.9% NaCl s.c. The animals were sacrificed by decapitation 36 hours after the last injection. The brain tissue was quickly removed, cut in half sagittaly, frozen on dry ice and maintained at À80 C.
Receptor autoradiography assays
Frozen mouse half-brains were sectioned sagittaly on a cryostat at approx. À20 C to 8 mm thickness. The sections were thaw-mounted on to poly-L-lysine coated slides and directly refrozen in the cryostat. The slides were stored at À80 C until use.
[
H] MK-801 autoradiography
Frozen sections were thawed at room temperature for 30 min, followed by a 15 min pre-incubation at room temperature in 50 mM Tris-Acetate buffer, pH 7.4. The sections were then incubated in the same buffer, containing 10 nM [ 10 min each in binding buffer at room temperature, followed by a rinse in distilled water at 4 C. The sections were dried in room temperature over night and then placed together with [ [
H]Cytisine autoradiography
Frozen sections were thawed at room temperature for 30 min, followed by a 60 min pre-incubation at room temperature in binding buffer, 50 mM Tris-HCl buffer pH 7.4 containing 120 mM NaCl, 5 mM KCl, 1 mM MgCl 2 and 2.5 mM CaCl 2 . The sections were then incubated in the same buffer containing 2 nM [ 3 H]Cytisine at room temperature for 60 min. Non-specific binding was determined in the presence of 100 mM (-)-nicotine. The incubation was terminated by three washes of 3 min each in binding buffer at room temperature, followed by a rinse in distilled water at 4 C. The sections were dried in room temperature and then placed together with [ [
I]abungarotoxin autoradiography
Frozen sections were thawed at room temperature for 30 min, followed by a 30 min pre-incubation at room temperature in binding buffer, 50 mM Tris-HCl buffer pH 7.4 containing 1 mg=ml BSA. The sections were then incubated in the same buffer containing 2 nM [ 125 I]abungarotoxin at room temperature for 120 min. Non-specific binding was determined in the presence of 1 mM abungarotoxin. The incubation was terminated by four washes of 5 min each in 50 mM Tris-HCl buffer pH 7.4 at 4 C, followed by a rinse in distilled water at 4 C. The sections were dried in room temperature and then placed together with [ I]microstandards. The regions analysed was cortex (frontal cortex, retrosplenial gr. cortex and motor cortex), hippocampus (CA1, CA2 and CA3), thalamus and caudate nucleus. The specific binding was calculated by subtracting the non-specific binding from the total binding.
The phospho-imaging screen ([3H]Cytisine) was quantified using the Fuji program Image Gauge 4.0. OD values were converted into fmol=mg tissue based on the standard curve derived from the [ 3 H]microstandards. The regions analysed was cortex (frontal cortex, retrosplenial gr. cortex and motor cortex), hippocampus, thalamus and caudate nucleus. The specific binding was calculated by subtracting the non-specific binding from the total binding.
Tissue preparation for western blot 5 animals of each group were used. Homogenates were prepared with ice-cold 50 mM sodium phosphate buffer (50 mM sodium phosphate, 50 mM NaCl, 2 mM EDTA, 2 mM EGTA and 1 mM phenylmethyl sulfonyl fluoride and Roche Diagnostics proteinase inhibitor cocktail, pH 7.4) and then centrifuged at 60.000Âg for 20 minutes. The resulting pellets were re-suspended in the icecold homogenate buffer with addition of 2% Triton X-100. The suspension was mixed for 2 h at 4 C and then centrifuged at 100.000Âg for 1 hour. The supernatant were used for western blot analysis. DC protein assay kit (Bio-Rad) was used to measure the protein content in the fractions.
Western blot
MAP-2 and synaptophysin were quantified by immunoblotting after resolution by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing conditions. For 258 C. Unger et al.
SDS-PAGE, 4-20% gradient minigels (12-15 wells, 20-15 ml, BioRad Ready Gel) were run at 150 mV constant voltages at room temperature for 60-70 minutes using the BioRad Protean II system. Running buffer (Tris=glycine=SDS, pH 8.3) and loading sample buffer were prepared and used according to the manufacturer's instructions, except that the transfer buffer contained SDS (0.0375% wt=vol) and methanol (20% vol=vol). Immediately after adding the loading buffer to the samples, it was incubated in a 95 C water bath for 10 minutes. The molecular mass markers were Cruz Marker MW (sc2035; Santa Cruz Biotechnologies, CA) and Kaleidoscope Prestained Standards (BioRad). The protein bands were blotted on a PVDF-membrane (RPN 303 F; Amersham Life Science) at 4 C with ice-cooling unit for 90 minutes for synaptophysin and 150 minutes for MAP-2, using a Mini-Trans-Blot electro blotting cassette system (170-3930; BioRad). Non-specific binding sites were blocked by incubating the blots in blocking buffer, MPBS-T 0.3% (5% wt=vol non-fat dried milk=0.3% vol=vol Tween-20=PBS, pH 7.5) for 1 hour at room temperature or overnight at 4 C. The blots were then incubated with either synaptophysin (1:2000) or MAP-2 (1:500) in MPBS-T 0.3% (containing 0.2%wt=vol Thimerosal) for 45 minutes at room temperature. They were then washed three times for 15 minutes using 1ÂPBS-T 0.2%, pH 7.4. After the washing step, each membrane was incubated with the appropriate secondary antibody in MPBS-T 0.3%, goat anti-rabbit (1:1000) for synaptophysin or donkey anti-mouse (1:2000) for MAP-2, for 1 hour at room temperature. The blots were washed as before and incubated for 5 minutes in 4 mL=blot of ECL Plus reagents (Amersham Life Science). Films (Hyper film ECL; Amersham Life Science) were exposed to the blots and developed according to standard procedures.
Image analysis of western blot
The films were scanned using a Sharp JX-325 scanner. The OD values of the bands were calculated as a product of contour OD and the area of the contour using Image Master 1D software (version 1.10; Pharmacia Biotech). All animals in one group were loaded on the same gel in duplicate with a pooled sample of all groups as a reference, allowing the comparison between groups. When all samples had been standardised to this pooled sample, setting the TgSaline group as 100% made comparison between the groups.
Statistical analysis
Statistical analysis of the autoradiographic data was carried out using two-way ANOVA followed by Scheffe Post Hoc Test to calculate the significance between hAChE-Tg and FVB=N as well as the significance of treatment with memantine on hAChE-Tg mice and FVB=N mice compared to saline treatment. For the western blot data, non-parametric Kruskal-Wallis test was used followed by Mann-Whitney to calculate the significance between hAChE-Tg and FVB=N as well as the significance of treatment with memantine on hAChE-Tg mice and FVB=N mice, respectively.
Results
Autoradiography
NMDA receptor binding sites
The regional distribution of NMDA receptor binding was determined by in vitro autoradiography using the radioligand Earlier studies in this transgenic mouse model have revealed a multileveled upregulation of several nAChR subunits, in particular the a4 subunit (Svedberg, 2002 (Svedberg, , 2003 . Similar to that observation, in this study there was a significant increase in the number of [ 3 H]Cytisine (a4 nAChR) binding sites in the frontal-(61%) (P<0.05), the retrosplenial-(46%) (P<0.05) and the motor cortex (47%) (P<0.01), as well as the thalamus (30%) (P<0.01) of the hAChE-Tg mice compared to the FVB=N mice (Fig. 2) . No changes in the number of (Fig. 3 ). There were no differences in any other brain region of hAChE-Tg compared to FVB=N controls. A significant increase of the [ 125 I]abungarotoxin binding sites was observed in the frontal-(59%) (P<0.01) and retrosplenial gr. cortex (65%) (P<0.01) in hAChE-Tg mice following treatment with memantine 20 mg=kg=day (Fig. 3) , while no changes occurred in any brain region of the FVB=N mice.
Western Blot
Synaptophysin levels in the cortex
To reveal whether enhanced expression of the human acetylcholinesterase induce abnormalities in the synapses, the levels of the synaptic marker synaptophysin was determined in the cortex of hAChE-Tg mice and FVB=N controls. No significant difference in synaptophysin levels was observed in the cortex of hAChE-Tg mice compared to the FVB=N mice (Fig. 4) . A significant increase of the synaptophysin levels following treatment with memantine was observed in both hAChE-Tg (P<0.05), and FVB=N mice (P<0.01) compared to saline treated animals (Fig. 4) .
MAP-2 levels in the cortex
The hAChE-Tg mice display morphologically reduced dendrite branching in the neocortex. Western blot showed no significant change in the levels of . A significant decrease in LMW MAP-2 levels in the cortex was however observed in the hAChE-Tg mice compared to the FVB=N mice (P<0.01) (Fig. 5) . We also wanted to determine whether memantine treatment might increase the MAP-2 levels in the cortex, reflecting an increase in the dendritic density. Memantine did not significantly alter the level of cortical HMW MAP-2 (Data not shown), while a significant increase in the levels of LMW MAP-2 was observed in both the hAChE-Tg (P<0.05) and the FVB=N (P<0.01) (Fig. 5) following treatment with memantine. 
Discussion
The results presented in this study show that the over-expression of AChE induces changes in the cholinergic as well as the glutamatergic neurotransmitter system. We also found that this might influence the levels of LMW MAP-2. An up-regulation of several nicotinic receptor subtypes is observed in hAChE-Tg mice, in particular these associated with the cholinergic terminals and participating in a compensatory response to the cholinergic impairment. A toxic effect of AChE on general brain function cannot be ruled out. AChE has been reported to have toxic effects both in neuron-and glia-like cell lines (Calder o on, 1998). In AD, there is a consistent presence of AChE in the senile plaques and studies have shown that AChE binds beta-amyloid (Ab) and promotes deposition (Alvarez, 1997 (Alvarez, , 1998 De Ferrari, 2001) . Recent studies in double transgenic hAChE-Tg=Tg2576 mice also support the notion that AChE accelerates Ab depostition (Rees, 2003) .
Several studies indicate that there exist a complex relationship between the cholinergic and the glutamatergic neurotransmission (Aigner, 1995; Maurice, 1994; Ohno, 1993) . The a7 nAChR are, besides located in cholinergic synapses, also are located presynapticly on glutamatergic axon terminals. Presynaptic nAChRs can enhance neurotransmitter release, and somatic or postsynaptic nAChRs can reduce the responsiveness of NMDA receptors, thereby influencing the ability of NMDA receptors to induce long-term synaptic plasticity (Albuquerque, 1997; Fisher, 2000; Gray, 1996; Radcliffe, 1998 Radcliffe, , 1999 . The observed decrease in NMDA receptor binding sites in the CA1 of the hippocampus and the thalamus of hAChE-Tg might be a result of the disrupted cholinergic transmission in these mice.
Neuroprotection represents a therapeutic intervention in order to prevent death of vulnerable neurons, slowing disease progression and delaying the transition from the preclinical to the clinical stage. It is of importance to try to enhance brain plasticity and maximising the recovery of the neurons. Different new treatment strategies of neurodegenerative diseases have been suggested to have neuroprotective effect, such as stimulation of the a7 nAChR (Nordberg, 2001) . Drugs targeting the NMDA subtype of the glutamate receptors are another mechanism, that has been suggested (Kemp, 2002) . Memantine is an uncompetitive NMDA receptor antagonist, with strong voltage-dependency and rapid blocking=unblocking kinetics. In addition, studies of memantine have revealed a substantially decreased neuropathology in a transgenic mouse model of HIV, by significantly improving both the dendritic-and the presynaptic terminal density (Toggas, 1996) .
In this study, treatment with memantine in the hAChE-Tg mice caused a significant increase in the a7 nAChR binding sites in the frontal-and retrosplenial gr. cortex compared to saline treated animals, while no effect was observed in the FVB=N mice treated with memantine. An up-regulation of the a7 nAChR in the cortex of hAChE-Tg mice following treatment with memantine may, in part, be a compensatory mechanism due to the cholinergic and glutamatergic alterations in this mouse model. These results may also further support the notion that the NMDA and a7 nAChRs have a close interaction in the brain. On the other hand, it is also important to remember that memantine are able to act as an open channel blocker on several other ligand gated ion channels, for instance the 5-HT3 receptors and the a4b2-and a7 nAChRs (Rammes, 2001; Buisson, 1998; Maskell, 2003) , and the changes observed following treatment with memantine may therefore have nothing to do with its interaction with the NMDA receptor, but instead reflect a direct interaction with the nAChRs or some other receptor.
In mature neurons MAP-2 is specifically localized in dendrites and has been proposed to play a role in neuritogenesis, synapse formation, and dendritic remodelling (Johnson, 1992) . It has been demonstrated that HMW MAP-2 localizes in dendrites and soma, and is almost absent in axons, and therefore, HMW MAP-2 is known as a dendro-somatic protein (Binder, 1984; Matus, 1988 Matus, , 1994 Riederer, 1985) . LMW MAP-2 is generally expressed in embryonic and early postnatal brains, and disappears dramatically with maturation of the central nervous system (Binder, 1984; Riederer, 1985) . Therefore, it is postulated that LMW MAP-2 is responsible for construction of neuronal and glial architectures in the developing brain (Johnson, 1992; Matus, 1988 Matus, , 1994 Tucker, 1990) . However, in regions of the adult brain that undergoes continuous neuronal remodelling, such as the olfactory system, LMW MAP-2 levels remain elevated. We observed that the hAChE-Tg mice displayed significant reduced LMW MAP-2 in the cortex compared to FVB=N, which might be in agreement with earlier findings of reduced dendritic branching in these mice (Beeri, 1997) . Interestingly enough, there were no differences in HMW MAP-2, suggesting that deficits in the cholinergic neurotransmitter system may only influence the LMW MAP-2 isoforms. These results must be further investigated and the molecular mechanisms carefully studied.
Memantine treatment increased the levels of LMW MAP-2 in both hAChETg and FVB=N, suggesting that memantine can influence the neuronal plasticity. It has been reported that activation of the NMDA receptors can induce activation of the calcium-dependent protein calpain, which selectively degrades MAP-2 (Felipo, 1993) . Antagonism of the NMDA receptor by memantine might thus decrease the proteolysis of MAP-2 by calpain. Activation of the a7 nAChR, leading to altered phosphorylation of MAP-2, might also be of importance (Miñ nana, 1998) . Phosphorylation of MAP-2 by cAMP-dependent protein kinase protects MAP-2 from cleavage by calpain (Alexa, 1996) . Synaptophysin, which is localized to the neuronal synaptic vesicles, is an marker for synaptic vesicles and presynaptic terminals (Hoog, 1988) . No difference in the levels of synaptophysin was observed in the cortex of hAChE-Tg compared to FVB=N mice. The cholinergic hypofunction does not seem to alter the number of presynaptic terminals in the cortex although the numbers of a4 and a7 nAChRs were increased. Memantine treatment significantly increased the presynaptic terminal density in the cortex of both hAChE-Tg and FVB=N mice, which might indicate that memantine have an effect on neurogenesis. NMDA receptor blockade by MK-801 has also been shown to enhance neurogenesis in the adult rat dentate gyrus (Okuyama, 2004) . The findings in this study raise the question of the possibilities of memantine to influence neurogenesis in the brain.
In conclusion, in this study we show that over-expression of AChE causes a marked increase in a4 nAChRs, but also a reduction in the number of NMDA receptors and LMW MAP-2 levels in the brain. Treatment with memantine in hAChE-Tg mice caused a significant increase in the number of cortical a7 nAChR binding sites as well as LMW MAP-2 and synaptophysin levels in brain cortex. Whether the effect of memantine on a7 nAChRs, synaptophysin-and LMW MAP-2 levels is a direct effect, or an indirect effect via the NMDA receptors, has to be further evaluated.
